Recombinant Human HepaCAM Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11598-HC

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11598-HC-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

  • R&D Systems CHO-derived Recombinant Human HepaCAM Fc Chimera Protein (11598-HC)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

CHO

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all HepaCAM Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human HepaCAM protein
Human HepaCAM
(Val34-Ser240)
Accession # Q19CZ8.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Val34

Predicted Molecular Mass

50 kDa

SDS-PAGE

60-80 kDa, under reducing conditions

Activity

Bioassay data are not available.

Scientific Data Images for Recombinant Human HepaCAM Fc Chimera Protein, CF

Recombinant Human HepaCAM Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human HepaCAM Fc Chimera Protein (Catalog # 11598-HC) was resolved with SDS-PAGE under reducing (R) condition and visualized by Coomassie® Blue staining, showing bands at 60-80 kDa, under reducing conditions.

Formulation, Preparation and Storage

11598-HC
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: HepaCAM

Hepatocyte cell adhesion molecule (HepaCAM), also known as glial cell adhesion molecule (GlialCAM), is a type I transmembrane glycoprotein in the Ig-superfamily that participates in cell migration and proliferation (ref). HepaCAM consists of an extracellular domain (ECD) with two C2 Ig-like domains, a transmembrane region, and an intracellular region containing a SH3 domain. Mature, human HepaCAM shares 99% amino acid sequence identity with mouse HepaCAM.  A second, truncated isoform is known to exist as a result of alternative splicing. Though first detected in the liver, HepaCAM expression has subsequently been detected in glial cells of the central nervous system. HepaCAM forms homodimers, through cis-interactions, on the cell surface and this interaction is known to modulate cell-matrix interactions. HepaCAM has been shown to suppress the growth of hepatocytes and is down-regulated in hepatocellular carcinoma in the liver. In the brain, HepaCAM is normally expressed in astrocytes where it regulates ion homeostasis, BBB physiology, and synaptic excitation. Loss of HepaCAM signaling has been reported to impair gap-junction cell coupling and the balance between synaptic excitation and inhibition. Multiple studies indicate that HepaCAM is a tumor suppressor candidate, but its exact role remains unknown. In Glioblastoma, HepaCAM helps mediate interactions, through its IgG-like domains, with proteins such as Mlc1 and aquaporin-4 and loss of HepaCAM expression results in a proinvasive environment. In prostate cancer, HepaCAM may help inhibit cancer progression as a reduction or absence of HepaCAM expression is seen in majority of cases. Additionally, HepaCAM is suppressed in multiple other carcinomas including breast, kidney, colon, rectum and stomach making it a potential therapeutic target.

References

  1. Moh, M. C., et al. (2005) J. Hepatol. 42:833.
  2. Moh, M.C., et al. (2005) 280:27366.
  3. Sofroniew, M.V. (2021) Neuron 109:2365.
  4. Baldwin, K.T. et al. (2021) Neuron 109:2427.
  5. De, A., et al. (2023) J Neurosci. 43:8043.
  6. Deng Q, et al. (2019) Mol Med Rep 19:2115.
  7. Moh, M.C., et al. (2008) Carcinogenesis 29:2298.

Long Name

Hepatocyte Cell Adhesion Molecule

Alternate Names

cancer susceptibility, FLJ25530, glial cell adhesion molecule, GLIALCAM, hepaCAM, hepatic and glial cell adhesion molecule, hepatocyte cell adhesion molecule, Protein hepaCAM

Entrez Gene IDs

220296 (Human)

Gene Symbol

HEPACAM

Additional HepaCAM Products

Product Documents for Recombinant Human HepaCAM Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human HepaCAM Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.